Evidence map›Paper›PMID 38539008›Full record

ReviewProbiotics and antimicrobial proteins2024

Unlocking the Potential of Probiotics: A Comprehensive Review on Research, Production, and Regulation of Probiotics.

Tales Fernando da Silva, Rafael de Assis Glória, Monique Ferrary Americo, Andria Dos Santos Freitas, Luis Claudio Lima de Jesus, Fernanda Alvarenga Lima Barroso, Juliana Guimarães Laguna, Nina Dias Coelho-Rocha, Laisa Macedo Tavares, Yves le Loir and 3 more

Open access · greenAbstract readReview
PubMed Publisher
In one paragraph

Review in Probiotics and antimicrobial proteins, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 1 pooled it
26.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 1 synthesis or guideline pooled it, 77 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 2 countries.

Tales Fernando da SilvaInstitute of Biological Sciences, Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-0237-9398
Rafael de Assis GlóriaInstitute of Biological Sciences, Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-4607-6364
Monique Ferrary AmericoInstitute of Biological Sciences, Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-6501-9533
Andria Dos Santos FreitasInstitute of Biological Sciences, Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-2498-7933
Luis Claudio Lima de JesusInstitute of Biological Sciences, Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0001-7708-3033
Fernanda Alvarenga Lima BarrosoInstitute of Biological Sciences, Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0001-8422-1131
Juliana Guimarães LagunaInstitute of Biological Sciences, Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-1032-4258
Nina Dias Coelho-RochaInstitute of Biological Sciences, Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-6941-9876
Laisa Macedo TavaresInstitute of Biological Sciences, Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Yves le LoirUMR1253, INRAE, L'Institut Agro Rennes Angers, STLO, Rennes, France.ORCID 0000-0002-0355-1065
Gwénaël JanUMR1253, INRAE, L'Institut Agro Rennes Angers, STLO, Rennes, France.ORCID 0000-0001-8694-3381
Éric GuédonUMR1253, INRAE, L'Institut Agro Rennes Angers, STLO, Rennes, France.ORCID 0000-0002-0901-4447
Vasco Ariston de Carvalho AzevedoInstitute of Biological Sciences, Department of Genetics, Ecology, and Evolution, Federal University of Minas Gerais, Belo Horizonte, Brazil. vasco@icb.ufmg.br.ORCID 0000-0002-4775-2280
Universidade Federal de Minas Gerais · BRInstitut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review provides a comprehensive overview of the current state of probiotic research, covering a wide range of topics, including strain identification, functional characterization, preclinical and clinical evaluations, mechanisms of action, therapeutic applications, manufacturing considerations, and future directions. The screening process for potential probiotics involves phenotypic and genomic analysis to identify strains with health-promoting properties while excluding those with any factor that could be harmful to the host. In vitro assays for evaluating probiotic traits such as acid tolerance, bile metabolism, adhesion properties, and antimicrobial effects are described. The review highlights promising findings from in vivo studies on probiotic mitigation of inflammatory bowel diseases, chemotherapy-induced mucositis, dysbiosis, obesity, diabetes, and bone health, primarily through immunomodulation and modulation of the local microbiota in human and animal models. Clinical studies demonstrating beneficial modulation of metabolic diseases and human central nervous system function are also presented. Manufacturing processes significantly impact the growth, viability, and properties of probiotics, and the composition of the product matrix and supplementation with prebiotics or other strains can modify their effects. The lack of regulatory oversight raises concerns about the quality, safety, and labeling accuracy of commercial probiotics, particularly for vulnerable populations. Advancements in multi-omics approaches, especially probiogenomics, will provide a deeper understanding of the mechanisms behind probiotic functionality, allowing for personalized and targeted probiotic therapies. However, it is crucial to simultaneously focus on improving manufacturing practices, implementing quality control standards, and establishing regulatory oversight to ensure the safety and efficacy of probiotic products in the face of increasing therapeutic applications.

Indexed as

ProbioticsAnimalsHumansFunctional characterizationHuman and animal modelsProbiogenomicsProbiotic regulationsProbiotics

Identifiers

PMID38539008
OpenAlexW4393276045

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.